Our news

20.03.2019

NeoPhore appoints Dr John Haurum as Non-Executive Director

Former F-star CEO joins the Board of Directors. NeoPhore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John…

27.04.2018

NeoPhore and PhoreMost Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme

Grant award funds expanded operations and recognizes innovative drug discovery programme 27th April 2018, Cambridge, UK – NeoPhore Limited, a cancer i…

11.04.2018

NeoPhore Appoints Jeffrey Roix as Chief Executive Officer

NeoPhore Limited, a cancer immuno-oncology company, today announced the appointment of Jeffrey Roix as Chief Executive Officer, with immediate…

08.01.2018

NeoPhore Appoints Pioneering Cancer Researchers and Clinicians to Scientific Advisory Board

Company attracts world-leading researchers who discovered the role of mismatch repair biology in cancer and cancer immunotherapy NeoPhore Limited, a…

Other news

08.02.2018

NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology

Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…

06.12.2017

UK’s NeoPhore pioneers new approach to cancer immunotherapy

Pharmaphorum: Newly launched UK biotech is looking to develop a new approach to immunotherapy, based around a seemingly paradoxical idea that…